Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director | August 09, 2021 | August 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date August 09, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.63 · Expires 2031-08-09 | Direct | 10,000 |
Reported balance
After 2021-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-09 · Grant · Acquired 10,000 · Balance 10,000 F1: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050952 · doc4.xml · derivative · entry 1 THOMPSON J STARK PHD · CIK 0001241146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.